

## **COCHRANE GYNAECOLOGY AND FERTILITY GROUP GUIDANCE**

- This guidance is in four sections, in the order that they appear in a published review
- For a new protocol, read part A below then go to part D
- For a full review or update, use all sections
- Examples below are in italics, while notes and comments from us are in plain text

<b>Cochrane Gynaecology and Fertility Group Guidance</b> .....	<b>1</b>
<b><i>PART A - ALL AUTHORS PLEASE READ - IT WILL SAVE YOU TIME!</i></b> .....	<b>2</b>
<b><i>PART B - Abstract</i></b> .....	<b>3</b>
<b><i>PART C - Plain language summary</i></b> .....	<b>4</b>
<b><i>PART D - Methods</i></b> .....	<b>6</b>
Criteria for considering studies for this review .....	6
Search methods for identification of studies .....	7
Data collection and analysis.....	8
Assessment of risk of bias in included studies .....	9
Measures of treatment effect .....	9
Unit of analysis issues .....	10
Dealing with missing data .....	10
Assessment of heterogeneity .....	10
Assessment of reporting biases .....	10
Data synthesis .....	11
Subgroup analysis and investigation of heterogeneity.....	11
Overall quality of the body of evidence: Summary of findings table.....	12
<b><i>PART E - Results</i></b> .....	<b>13</b>
Description of studies.....	13
Included studies.....	13
Excluded studies.....	13
Risk of bias in included studies .....	13
Effects of interventions.....	14
How to format your findings .....	16
<b><i>PART F - Discussion</i></b> .....	<b>17</b>
Summary of main results .....	17
Overall completeness and applicability of evidence .....	17
Quality of the evidence .....	17
Potential biases in the review process .....	18
Agreements and disagreements with other studies or reviews.....	18
<b><i>PART G - Authors' conclusions</i></b> .....	<b>18</b>
Implications for practice .....	18
Implications for research.....	18
Differences between protocol and review.....	18
<b><i>Appendix - Copy-Editing</i></b> .....	<b>19</b>

## ***PART A - ALL AUTHORS PLEASE READ - IT WILL SAVE YOU TIME!***

By far the most common problems with reviews involve the issues listed below:

### *Methods*

- In general, do not exclude studies on the basis of their reported outcome measures; take care to ascertain that relevant outcomes are not available because they have not been measured rather than simply not reported.
- Define in advance details of what are acceptable outcome measures (e.g. differing scales, time-points), and state a preference order when there are several possible measures.
- Keep subgroup analyses to an absolute minimum and explain the rationale for these.
- If planning any departures from Methods specified in protocol, check with editorial base first; document and justify any changes in the Changes from Protocol section.
- It is now mandatory for authors with our group to contact study authors in order to obtain or confirm data. This includes details to inform 'Risk of bias' assessments, details of interventions and outcomes, and study results.

### *Reporting results*

- Include all pre-specified comparisons and outcomes: if there are no relevant data, say so.
- Use the same order of comparisons and outcomes throughout the review.
- Use this format for presenting results: (RR 0.89, 95% CI 0.75 to 1.05, 3 RCTs, N = 811,  $I^2 = 31%$ , low-quality evidence).
- Interpret the main findings in absolute terms e.g. if 10% of women taking placebo experience pain, between 2% and 5% of those using XX will do so.
- Do not confuse lack of evidence of an effect with evidence of a lack of effect: say something like "There was insufficient evidence to determine whether there was a difference" not "There was no significant difference".
- As "no evidence of a difference" may imply equivalence, we don't use this anymore (see p.16 for more information on How to format your findings).
- Consider clinical rather than statistical significance.
- Interpret subgroups very cautiously. In general, do not report them in the abstract.
- If investigating subgroup differences, present an overall plot or figure containing all subgroups, rather than multiple forest plots.
- Include the sample size for each included study and for each intervention group in the Characteristics of Included Studies table.
- It is mandatory to conduct sensitivity analyses for the primary outcomes restricted to studies with low selection bias.
- If the odds of an outcome (beneficial e.g. live birth or detrimental e.g. adverse effects) increase with the intervention, display it graphically in the meta-analyses to the right of the centre-line. If the odds of an outcome decrease with the intervention, display it on the left of the centre-line.

### *Conclusions*

In summary parts of the review Abstract, Plain language summary and SoF:

- Include the same outcomes: include all **main outcomes** (these include the primary outcomes + prespecified secondary outcomes; should be based on clinical importance; don't forget adverse events)
- Include the same comparisons: those that are clinically most important. These should be specified at the protocol stage, rather than on the basis of the results.
- Incorporate the findings of the GRADE assessment.
- Be 100% consistent.

### *Summary of findings table*

- Specify detailed plans for the SoF table in the Methods section (see page 12 below).
- The SoF should be prepared once the study data have been entered, and before the results section is written.

- Include max 7 **main outcomes** (primary outcomes + prespecified secondary outcomes)
- Clearly explain Summary of Findings (SoF) evidence downgrades in footnotes: e.g. We downgraded the evidence by two levels, due to very serious imprecision: only 29 events
- When you reach this stage, before proceeding any further please submit your review to our Managing Editor for an editorial check.
- For help with preparing a summary of findings table, contact us or visit [GRADEpro](#) [GDT](#).

## **PART B - Abstract**

### *Background*

*Treatment B is commonly used to optimize the chance of live birth in women undergoing assisted reproductive technology (ART). However, it is known to increase multiple pregnancy rates, potentially causing maternal and perinatal morbidity. Treatment A is an alternative intervention which may reduce the risk of multiple pregnancy. We compared the benefits and risks of the two treatments*

### *Objectives*

*To evaluate the effectiveness and safety of Treatment A in women undergoing ART.*

### *Search Methods*

*The Cochrane Gynaecology and Fertility (CGF) Group trials register, CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL and two trials registers were searched in August 2016 together with reference checking and contact with study authors and experts in the field to identify additional studies.*

### *Selection criteria*

*We included randomized controlled trials (RCTs) of the use of Treatment A compared with Treatment B for subfertile women.*

### *Data collection and analysis*

*We used standard methodological procedures recommended by Cochrane. The primary review outcomes were cumulative live birth and multiple pregnancy. Other adverse effects were a secondary outcome.*

### *Main results*

*We included three RCTs (811 women analysed). The evidence was low to moderate quality: the main limitations were serious risk of bias due to poor reporting of study methods, and serious imprecision.*

## **Treatment A vs Treatment B**

*There may be little or no difference in cumulative live birth rate between Treatment A and Treatment B (RR 1.00, 95% CI 0.92 to 1.09, 4 RCTs, N = 3492,  $I^2=0$ , moderate-quality evidence). The evidence suggests that if the chance of live birth following Treatment B is assumed to be 37%, the chance following Treatment A would be between 34% and 40%.*

*Treatment A probably reduces multiple pregnancy rates compared with Treatment B (RR 0.04, 95% CI 0.01 to 0.15, 3 RCTs, N = 811,  $I^2=23\%$ , moderate-quality evidence). This suggests that if the risk of multiple pregnancy following Treatment B is assumed to be 13%, the risk following Treatment A would be between 0% and 2%.*

*There was insufficient evidence to reach a conclusion regarding other adverse effects, as no studies reported data suitable for analysis.*

### *Authors' conclusions*

*Treatment A probably reduces the risk of multiple pregnancy in women undergoing ART without substantially reducing the cumulative live birth rate. Data were lacking on other adverse effects.*

- Report all main outcomes as explained on page 2
- Do not report subgroup analyses in the abstract.
- Organise the abstract by comparison rather than by outcome.
- Always report outcomes in the same order.
- Aim to limit the abstract to fewer than 700 words. Absolute maximum is 1000.

### **PART C - Plain language summary**

**Title: Treatment A versus treatment B for women undergoing assisted reproductive technology (ART)**

#### *Review question*

*Cochrane authors reviewed the evidence about the effect of Treatment A versus Treatment B in women undergoing ART.*

#### *Background*

*Treatment B is commonly used to increase the chance of live birth in women undergoing ART. However, it is known to increase multiple pregnancy rates, which can cause serious health risks for both mother and baby. Treatment A is an alternative approach which may reduce the risk of multiple pregnancy. We compared the benefits and risks of the two treatments.*

#### *Study characteristics*

*We found 3 randomised controlled trials comparing Treatment A with Treatment B in a total of 811 women undergoing ART. The evidence is current to June 2016.*

#### *Key results*

*Treatment A probably reduces the risk of multiple pregnancy in women undergoing ART without substantially reducing the cumulative live birth rate. Data were lacking on other adverse effects.*

*The evidence suggests that if the chance of live birth following Treatment B is assumed to be 37%, the chance following Treatment A would be between 34% and 40%. It also suggests that if the risk of multiple pregnancy following Treatment B is assumed to be 13%, the risk following Treatment A would be between 0% and 2%. Evidence on other adverse events was poorly reported and inconclusive.*

#### *Quality of the evidence*

*The evidence was of low to moderate quality. The main limitations in the evidence were poor reporting of study methods, and lack of precision in the findings for live birth.*

- Format the plain language summary under the five headings used above
- For more detailed information on the standards for Plain language summaries go to: [Standards for the reporting of Plain Language Summaries in new Cochrane Intervention Reviews](#)



- Translate the effect estimates for important clinical outcomes into language that uses natural frequencies. Rates per 100 (as used above) are easily extracted from the review's Summary of Findings Table.
- Report and interpret the units used for continuous outcomes (e.g. a VAS scale of 0-10 where 0 is pain-free and 10 is unbearable pain)
- Report all main outcomes in the Abstract and PLS, and summarise any evidence about adverse effects (including lack of data).
- Aim to limit the PLS to fewer than 400 words. Absolute maximum is 700.

## *PART D - Methods*

### **Criteria for considering studies for this review**

#### *Types of studies*

*Randomised controlled trials (RCTs) will be included*

- Usually all randomised trial designs should be included. A common exception is crossover trials in situations where treatment success precludes “crossover” (e.g. in subfertility trials, where the goal is pregnancy/live birth). Various acceptable options exist:
- Crossover trials will be excluded, as the design is not valid in this context
- Crossover trials will be included but only data from the first phase will be included in meta-analyses, as the crossover is not a valid design in this context.
- Crossover trials will be included, as the crossover is a valid design in this context
- Define any potentially ambiguous terms, such as “double-blind”.

#### *Types of participants*

*Women/couples with unexplained infertility will be eligible for inclusion.*

- Definitions of the condition (e.g. unexplained infertility) belong in the Background section.

#### *Types of interventions*

*Trials comparing Factor X via any route versus any other active intervention or placebo will be included*

#### *Types of outcome measures*

##### **Primary outcomes**

1. *Live birth or ongoing pregnancy*
  - *Live birth is defined as delivery of a live fetus after 20 completed weeks of gestation*
  - *Ongoing pregnancy is defined as evidence of a gestational sac with fetal heart motion at 12 weeks, confirmed with ultrasound*
2. *Multiple pregnancy*

##### **Secondary outcomes**

3. *Clinical pregnancy, defined as evidence of a gestational sac, confirmed by ultrasound.*
4. *Any adverse event (including miscarriage, bleeding, drug reactions), reported either as a composite measure or separately.*
5. *Quality of life. If studies report more than one scale, preference will be given to the SF-36, then other validated generic scales, and finally condition-specific scales.*
  - You can combine ongoing pregnancy data with live birth data in one primary outcome live birth/ongoing pregnancy only if ongoing pregnancy is directly reported in the trial (not by calculating it from clinical pregnancy). In the absence of live birth data, you should report ongoing pregnancy separately.
  - In general, avoid excluding studies based on outcomes. Check whether outcomes were measured, rather than whether they were reported.
  - The primary outcomes should normally include one measure of effectiveness (e.g. live birth) and one of potential harm (e.g. multiple pregnancy).
  - Decide which seven outcomes (max) will be included in the Summary of findings table.
  - Number outcomes as in the example above and use the same numbers in the Effects of Interventions section.
  - Keep secondary outcomes to a minimum. Focus on clinical outcomes and try to avoid lab outcomes (e.g. implantation rate).
  - Define in advance details of what are acceptable outcome measures (e.g. differing definitions, assessors, scales, time-points) and state a preference order when there are several possible measures.



## Search methods for identification of studies

*We will search for all published and unpublished RCTs of XX, without language restriction, in consultation with the Gynaecology and Fertility Group (CGF) Information Specialist.*

### Electronic searches

(1) *We will search the following electronic databases for relevant trials:*

1. *The Cochrane Gynaecology and Fertility Group (CGF) Specialised Register of Controlled Trials, PROCITE platform (from inception onwards)*
2. *CENTRAL; via the Cochrane Register of Studies Online (CRSO Web platform) (from inception onwards)*
3. *MEDLINE Epub Ahead of Print, In-Process & Other Non-Indexed Citations) Ovid (from 1946 onwards);*
4. *Embase Ovid (1980 onwards);*
5. *PsycINFO Ovid (from 1806 onwards)*
6. *AMED Ovid; (from 1985 onwards) (for any complementary therapy review topics)*

*The MEDLINE search will be combined with the Cochrane highly sensitive search strategy for identifying randomized trials which appears in the Cochrane Handbook of Systematic Reviews of Interventions (Version 5.1.0 chapter 6, 6.4.11). The Embase and PsycINFO searches are combined with trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN) <http://www.sign.ac.uk/search-filters.html>.*

(2) *Other electronic sources of trials will include*

1. *LILACS and other Spanish and Portuguese language databases (Latin American and Caribbean Health Science Information database (from 1982 ongoing). found in the Virtual Health Library Regional Portal (VHL) <http://pesquisa.bvsalud.org/portal/> (the right hand drop down box allows you to filter out MEDLINE records)*
2. *Google Scholar (for recent trials not yet indexed in the major databases) [The searches above will be simple short keyword searches, only checking the top few hits, and should also be documented in the appendices]*
3. *Epistemonikos database <https://www.epistemonikos.org/>, a multilingual database of health evidence (the largest source of systematic reviews and also other scientific evidence).*

### Searching other resources

(3) *We will hand search reference lists of relevant trials and systematic reviews retrieved by the search and contact experts in the field to obtain additional data. We will also hand search relevant journals and conference abstracts that are not covered in the CGF register, in liaison with the Information Specialist. We will contact original authors for clarification and further data if trial reports are unclear. We will not perform a separate search for adverse effects of interventions used for the treatment XX. We will consider adverse effects described in the studies only.*

### Gynaecology and Fertility search requirements:

Designing and running the search

- The Gynaecology and Fertility Information Specialist (IS) (Marian Showell) will help design your search and will run a search in the electronic databases listed under (1) above. It is the responsibility of the review authors to run, document and date (with day, month and year) the searches of other sources (i.e. those listed under (2) and (3) above, as appropriate).
- Please note that <http://www.clinicaltrials.gov> and <http://apps.who.int/trialsearch> (the World Health Organisation International Trials Registry Platform search portal) are now indexed in CENTRAL with 1 month delay. Authors can search these databases if they wish to cover the 1 month lag, but this is not mandatory.

- As from July 2020 CINAHL records are being automatically downloaded to CENTRAL so the IS no longer searches CINAHL as an individual database.
- Review authors MUST search reference lists of articles retrieved and contact experts in the field in order to obtain any additional studies
- Reviews of Traditional Chinese Medicine or Chinese complementary therapies must search at least one Chinese database
- Epistemonikos database is a good source of systematic reviews, for reference checking
- Liaise with the CGF Information Specialist to avoid duplication of handsearching and for other advice on searching
- List all sources searched in the Methods section of the review (as in the example above).
- The search process should be summarised in a PRISMA flow diagram in the full review.
- Full search strategies for all sources searched must be copied and pasted into the appendices (not in the body of the text) of the review along with dates and the platforms used for each database.
- The MEDLINE, Embase, PsycINFO, and AMED searches are on the OVID platform, CENTRAL is now searched via CRS ONLINE via the Web.
- In the protocol the numbers of hits per search line (i.e. the numbers in brackets after the keywords) are removed from the strategies, however at the review stage the numbers of hits per keyword remain.
- The ‘assessed as up to date’ date in the header of your review must be the same as the date of the searches that have been incorporated in the review.
- It is mandatory to run/update searches for all relevant databases no more than six months (maximum 12 months) before publication of the full review.
- Ideally any new studies should be fully incorporated. As a minimum, potentially eligible studies should be referenced under “awaiting classification” or “ongoing”, but authors have to show that they are waiting for information from trial authors.

## Data collection and analysis

There should not be any text under this heading.

### *Selection of studies*

*After an initial screen of titles and abstracts retrieved by the search, conducted by XXX\*, we will retrieve the full texts of all potentially eligible studies. Two review authors (XX and YY) will independently examine these full text articles for compliance with the inclusion criteria and select eligible studies. We will correspond with study investigators as required, to clarify study eligibility. Disagreements will be resolved by discussion. If any reports require translation, we will describe the process used for data collection. We will document the selection process with a “PRISMA” flow chart.*

- **\*It is mandatory that two people independently do this initial screen**

### *Data extraction and management*

*Two review authors will independently extract data from eligible studies using a data extraction form designed and pilot-tested by the authors. Any disagreements will be resolved by discussion. Data extracted will include study characteristics and outcome data (see data extraction table for details, Appendix XX). Where studies have multiple publications, the authors will collate multiple reports of the same under a single study ID with multiple references. We will correspond with study investigators for further data on methods and/or results, as required.*

- Data are often presented in a non-standardised format. Studies should be included irrespective of whether outcomes are reported in a “usable” way. In multi-arm studies, data from arms that do not meet eligibility criteria should be excluded.



### Assessment of risk of bias in included studies

*Two review authors will independently assess the included studies for risk of bias using the Cochrane risk of bias assessment tool (Higgins 2011) to assess: selection (random sequence generation and allocation concealment); performance (blinding of participants and personnel); detection (blinding of outcome assessors); attrition (incomplete outcome data); reporting (selective reporting); and other bias. Judgements will be assigned as recommended in the Cochrane Handbook Section 8.5 (Higgins 2011). Disagreements will be resolved by discussion. We will describe all judgements fully and present the conclusions in the Risk of Bias table, which will be incorporated into the interpretation of review findings by means of sensitivity analyses (see below). With respect to within-trial selective reporting, where identified studies fail to report the primary outcome of live birth, but do report interim outcomes such as pregnancy, we will assess whether the interim values are similar to those reported in studies that also report live birth.*

- Read section 8.5 of the handbook for detailed guidance on assessing each type of bias
- If likely sources of “other bias” can be identified in advance, these should be specified in this section and the number of domains increased accordingly.
- Assessment of risk of bias involves considering the potential impact of each domain in the context of individual studies (or even individual outcomes). For example, lack of blinding may not increase the risk of bias if follow-up is complete and outcomes are unequivocal (e.g. live birth).
- Selective reporting is a type of reporting bias that affects the internal validity of an individual study. It refers to the selective reporting of some outcomes (e.g. positive outcomes) and the failure to report others (e.g. adverse events). Trialists should report all pre-stated outcomes, which should include all outcomes that you would expect, such as adverse events.

### Measures of treatment effect

*For dichotomous data (e.g. live birth rates), we will use the numbers of events in the control and intervention groups of each study to calculate Mantel-Haenszel odds ratios (ORs) or (where events are very rare) Peto ORs\*. For continuous data (e.g. weight gain), if all studies report exactly the same outcomes we will calculate mean difference (MDs) between treatment groups. If similar outcomes are reported on different scales (e.g. change in weight) we will calculate the standardised mean difference (SMD). We will reverse the direction of effect of individual studies, if required, to ensure consistency across trials. We will treat ordinal data (e.g. quality of life scores) as continuous data. We will present 95% confidence intervals for all outcomes. Where data to calculate ORs or MDs are not available, we will utilise the most detailed numerical data available that may facilitate similar analyses of included studies (e.g. test statistics, p values). We will assess whether the estimates calculated in the review for individual studies are compatible in each case with the estimates reported in the study publications.*

- \*There are three available statistics to analyse binary (dichotomous) outcomes - the odds ratio, risk ratio and risk difference. The odds ratio further divides into the Mantel-Haenszel and Peto estimates. Any analysis compatible with the Handbook (please see chapter 9) is acceptable although it is rarely appropriate to use a risk difference. We recommend use of the odds ratio (Mantel Haenszel by default, Peto if events are very rare) because of its superior mathematical properties. Whichever statistic you use, we

encourage 'translation' of the result to actual percentages for a typical population to maximise understanding. You will find examples of this in Sections B, C and E.

- Only include information relevant to the review (e.g. many subfertility reviews contain only binary outcomes, so you do not need to provide for continuous outcomes.)

### Unit of analysis issues

*The primary analysis will be per woman randomised; per pregnancy data may also be included for some outcomes (e.g. miscarriage). Data that do not allow valid analysis (e.g. "per cycle" data) will be briefly summarised in an additional table and will not be meta-analysed. Multiple births will be counted as one live birth event. Only first-phase data from crossover trials will be included. [OR: Statistical advice will be sought regarding the analysis of crossover trials, to facilitate the appropriate inclusion of crossover data in meta-analysis].*

- If studies report only "per cycle" data, contact authors and request "per woman" data.
- Some outcomes can only occur in women who reach clinical pregnancy (e.g. multiple pregnancy, miscarriage, etc) Report all outcomes per randomised woman, as this is the unit of randomisation. Rates per clinical pregnancy may be used as the denominator for a sensitivity analysis, as this will help give the full picture.

### Dealing with missing data

*We will analyse the data on an intention-to-treat basis as far as possible (i.e. including all randomised participants in analysis, in the groups to which they were randomised). Attempts will be made to obtain missing data from the original trialists. Where these are unobtainable, we will undertake imputation of individual values for live birth only: live birth will be assumed not to have occurred in participants without a reported outcome. For other outcomes, we will analyse only the available data. Any imputation undertaken will be subjected to sensitivity analysis (see below).*

*If studies report sufficient detail to calculate mean differences but no information on associated standard deviation (SD), we will assume the outcome to have a standard deviation equal to the highest SD from other studies within the same analysis.*

### Assessment of heterogeneity

*We will consider whether the clinical and methodological characteristics of the included studies are sufficiently similar for meta-analysis to provide a clinically meaningful summary. We will assess statistical heterogeneity by the measure of the  $I^2$ . An  $I^2$  measurement greater than 50% will be taken to indicate substantial heterogeneity (Higgins 2011).*

### Assessment of reporting biases

*In view of the difficulty of detecting and correcting for publication bias and other reporting biases, we will aim to minimise their potential impact by ensuring a comprehensive search for eligible studies and by being alert for duplication of data. If there are ten or more studies in an analysis, we will use a funnel plot to explore the possibility of small study effects (a tendency for estimates of the intervention effect to be more beneficial in smaller studies).*

- This section on reporting biases refers to review-wide reporting bias (e.g. publication bias, multiple publication bias, language bias etc), whereby the dissemination of research findings is influenced by the nature and direction of results, reducing the likelihood that all studies eligible for a review will be retrieved.

## Data synthesis

*If the studies are sufficiently similar, we will combine the data using a fixed effect/random effects\* model in the following comparisons:*

1. *Factor X versus placebo, subgrouped by mode of administration and dose. We plan to pool the data*
  - (i) *Low dose oral*
  - (ii) *High dose oral*
2. *Factor X versus Factor G*
3. *Factor X versus Factor H*

Statistical analysis will be performed using Review Manager 5.3 (RevMan 2014).

- Define analyses that are comprehensive and mutually exclusive, so that all results can be slotted into one category only, and so that trials within the same category can sensibly be pooled. This allows consideration of effects within each category as well as, or instead of, an overall estimate for the comparison.
- If analyses are subgrouped (as in example 1 above), state whether it is planned to pool the subgroups
- \*In general, fixed-effect analysis can be used if it is reasonable to assume that the underlying effect size is the same for all the trials in the analysis. Otherwise consider using random-effects analysis to obtain an overall summary, or do not combine the trials. It is important that you can justify whatever decision you make.
- If the odds of an outcome (beneficial e.g. live birth or detrimental e.g. adverse effects) increase with the intervention, display it graphically in the meta-analyses to the right of the centre-line. If the odds of an outcome decrease with the intervention, display it on the left of the centre-line.

## Subgroup analysis and investigation of heterogeneity

*Where data are available, we will conduct subgroup analyses to determine the separate evidence within the following subgroups:*

1. *Studies of low dose versus studies of high dose*
2. *Studies including only women with a high BMI (>32kg/m<sup>2</sup>)*

*If we detect substantial heterogeneity, we will explore possible explanations in subgroup analyses (e.g. differing populations) and/or sensitivity analyses (e.g. differing risk of bias). We will take any statistical heterogeneity into account when interpreting the results, especially if there is any variation in the direction of effect.*

- Keep subgroups to an absolute minimum
- Subgroups can be defined either by characteristics of the study or by those of the participants. In practice, the latter are unlikely to be available in reported data. Subgroups should be explicit and few. Preferably the rationale for each will be clear from the Background section. If not, it must be explained here.
- If subgroups are to be compared, this should be done with a formal statistical test. Interpretation of the statistical analysis for subgroups is problematic.

### Sensitivity analysis

*We will conduct sensitivity analyses for the primary outcomes to determine whether the conclusions are robust to arbitrary decisions made regarding the eligibility and analysis. These analyses will include consideration of whether the review conclusions would have differed if:*

1. *Eligibility had been restricted to studies at low risk of bias, defined as studies at low risk of selection bias*
  2. *A [fixed effect/random effects (delete one!)] model had been adopted*
  3. *Alternative imputation strategies had been implemented*
  4. *The summary effect measure had been relative risk rather than odds ratio*
- Investigating whether the conclusions are robust is of utmost importance. As a minimum, authors should **perform sensitivity analyses for all primary outcomes restricted to trials with low risk of selection bias.**

### Overall quality of the body of evidence: Summary of findings table

*We will prepare a Summary of findings table using GRADEpro and Cochrane methods (Higgins 2011; GRADEpro GDT 2015). This table will evaluate the overall quality of the body of evidence for the main review outcomes (Live birth, ongoing pregnancy, multiple pregnancy, OHSS) for the main review comparison (Treatment A versus Treatment B). Additional Summary of Findings tables will be also prepared for the main review outcomes for other important comparisons (Treatment A versus placebo, and Treatment B versus Treatment C). We will assess the quality of the evidence using GRADE criteria: risk of bias, consistency of effect, imprecision, indirectness and publication bias). Judgements about evidence quality (high, moderate, low or very low) will be made by two review authors working independently, with disagreements resolved by discussion. Judgements will be justified, documented, and incorporated into reporting of results for each outcome.*

*We plan to extract study data, format our comparisons in data tables and prepare a summary of findings table before writing the results and conclusions of our review.*

- The SoF for the main comparison will appear at the front of the published review
- Additional SoFs can be prepared for other important comparisons (those reported in full in the abstract) but it is not essential to have an SoF for every comparison
- Include a maximum of seven outcomes on each SoF (main outcomes-these include primary outcomes + prespecified secondary outcomes)
- Include the same outcomes for each comparison
- The same comparisons and outcomes should be reported in the abstract as in the SoF
- For examples of how and when to down grade evidence see the GRADE handbook [chapter 5](#) and [How to grade](#).

Higgins 2011: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from [handbook.cochrane.org](http://handbook.cochrane.org).

GRADEpro GDT 2015

GRADEpro GDT [Computer program]. Version accessed XXX (for full review or update insert date that applies). Hamilton (ON): GRADE Working Group, McMaster University, 2015. Available at [grade.pro.org](http://grade.pro.org).

## **PART E - Results**

### **Description of studies**

#### *Results of the search*

*The search retrieved 97 articles. Ten studies (12 articles) were potentially eligible and were retrieved in full text. Three studies (four articles) met our inclusion criteria. We excluded five studies and two are ongoing. See study tables: Characteristics of included studies, Characteristics of excluded studies, Characteristics of studies awaiting classification.*

- Include a PRISMA flow chart – insert as a figure

### **Included studies**

- No text should appear directly under this heading. Insert four subheadings (as below) and briefly summarise important points. Include full details of individual studies in Characteristics of included studies table (not this section).

#### *Study design and setting*

*Three parallel-design randomised controlled trials (RCTs) were included. All were multicentre studies conducted in ART clinics in the Netherlands or the UK.*

#### *Participants*

*The studies included 811 subfertile women undergoing ART. Their mean age ranged across studies from 32 to 37 years.*

#### *Interventions*

*All three studies compared Treatment A with Treatment B*

#### *Outcomes*

*All three studies reported live birth and multiple pregnancy*

*All three studies also reported other adverse effects, but none included data suitable for analysis*

### **Excluded studies**

*Five studies were excluded from the review, for the following reasons:*

- 3/5 were not RCTs
- 2/5 did not compare Treatment A versus Treatment B
  
- Only studies that initially appeared eligible should be listed as excluded studies (i.e. if you had to read the full-text publication in order to determine that it was ineligible)

### **Risk of bias in included studies**

#### *Allocation (Selection bias)*

Address both generation of random sequence and allocation concealment under this heading. Use separate paragraphs or subheadings.

#### *Sequence generation*

*One study was rated as at low risk of selection bias related to sequence generation, as it used computer randomisation or a random numbers table. The other two studies did not describe the method used and were rated as at unclear risk of this bias.*

#### *Allocation concealment*

*One study was rated as at low risk of selection bias related to allocation concealment as it used sequentially labeled, sealed, opaque envelopes. The other two studies failed to describe methods of allocation concealment and we rated these as at unclear risk of bias for this domain.*

#### *Blinding of participants and personnel (Performance bias)*



### *Blinding of outcome assessors (Detection bias)*

*We did not consider that blinding was likely to influence findings for the primary review outcomes (live birth and multiple pregnancy). Blinding might influence outcomes for other adverse events, but no studies reported relevant data for this outcome.*

- Consider the degree to which blinding is likely to influence specific outcomes.

### *Incomplete outcome data (Attrition bias)*

*All three studies analysed all or most (>95%) of the women randomised and we judged them to be at low risk of attrition bias.*

### *Selective reporting (Reporting bias)*

*We rated all three studies as at low risk of selective reporting bias. All outcomes planned in the protocols were reported and these included live birth and multiple pregnancy (i.e. the most clinically relevant outcomes).*

*We rated xx studies as at unclear risk of bias although they reported our review's primary outcomes; we could not obtain a study protocol and the study was not prospectively registered so there was no information we could use to verify study details.*

### *Other potential sources of bias (Other bias)*

*In one study there was a statistically significant baseline difference in age between the two groups and the risk of bias was deemed unclear. We found no potential sources of within-study bias in the other two studies.*

- Do not include funding source, power calculations or ethics approval in this section, as they do not affect internal validity. These issues should be reported in the Characteristics of Included Studies table. If issues such as funding are of concern, they can be reported in the Results section (Description of studies), and the Discussion section (Quality of the evidence).

For examples on criteria for judging risk of bias in all domains, visit [Criteria for judging risk of bias in the 'Risk of bias' assessment tool](#).

## **Characteristics of included studies tables**

- Participants: include here the numbers randomized to each intervention and control group
- **Use the Notes section to record the following:**
  - Clinical trial registration number – check this was *prospective* registration
  - Study dates
  - Funding
  - Conflicts of interest
  - Whether they contacted trial authors for missing information relating to data, RoB, etc. as necessary.

## **Effects of interventions**

Notes – authors please read and implement!

- Separate primary and secondary outcomes.
- Use the same order of comparisons and outcomes and numbering system as in your Methods section and data tables.
- Include all pre-specified comparisons and outcomes: if there are no relevant data, say so
- Use this format for presenting results: (RR 0.89, 95% CI 0.75 to 1.05, 3 RCTs, N = 811, I<sup>2</sup> = 31%, low-quality evidence).

- Report and interpret the units used for continuous outcomes (e.g. a VAS scale of 0-10 where 0 is pain-free and 10 is unbearable pain): report this in the Abstract, main text and the 'comment's section of the SoF table.
- Do not confuse lack of evidence of an effect with evidence of a lack of effect: say something like "There was insufficient evidence to determine whether there was a difference" not "There was no significant difference".
- As "no evidence of a difference" may imply equivalence, we do not use this unless the evidence does indeed suggest equivalence.
- Consider clinical rather than statistical significance.
- If there are multi-arm studies, avoid double-counting of controls.
- Do not describe the results of individual studies unless there is only one study in the comparison.
- If presenting multiple sensitivity analyses or different ways of subgrouping the same studies, present these in summary form (e.g. a single Table or Figure) and not in multiple forest plots.
- Report all pre-specified sensitivity and subgroup analyses at the end of each comparison. If there were too few studies to conduct the analyses, state this.
- Interpret subgroups very cautiously. In general, do not report them in the abstract.
- Report any post-hoc analyses at the end of each comparison, noting that they were not pre-specified and that they require extra caution in interpretation.
- Report the results of funnel plots E.g. "Funnel plots for the primary outcomes (live birth and ongoing pregnancy) did not suggest reporting bias".
- If there were too few studies to construct a funnel plot, state this in the results section.
- Acknowledge any substantial statistical heterogeneity detected and explore it (e.g. by means of subgroup analyses).
- Explain the effect estimates for important clinical outcomes in a user-friendly way. We suggest using percentages (as in the example on page 3), derived from the Summary of findings table
  - Use the assumed and corresponding risks columns of the SoF, made into a percentage and rounded up.

Outcome	Assumed risk (control)	Corresponding risk (intervention)	Relative effect	No of participants (studies)	Quality of the evidence	Comment
	TVUS plus serum estradiol	TVUS alone				
Clinical pregnancy	349 per 1000	360 per 1000 (287 to 442)	OR1.05 (0.75 to 1.48)	602 (4 studies)	⊕⊕⊕⊖ moderate	-

- 'translation' would be:
  - This suggests that in women with a 35% chance of clinical pregnancy using monitoring with TVUS plus serum estradiol, the clinical pregnancy rate in women using TVUS alone will be between 29% and 44%*
- If there are no data for an outcome, then you say so. A finding of no evidence is in itself an important finding, and can form the basis of the Implications for research section.

## How to format your findings:

### 1. Comparison of Treatment A versus Treatment B

#### Primary outcomes

##### 1.1 Live birth

There may be little or no difference in cumulative live birth rate between Treatment A and Treatment B (RR 1.00, 95% CI 0.92 to 1.09, 4 RCTs, N = 3492,  $I^2 = 0$ , moderate-quality evidence). This suggests that if the chance of live birth following Treatment A is assumed to be 37%, the chance following Treatment B would be between 34% and 40%. There were too few studies to conduct any planned sensitivity analyses.

##### 1.2 Multiple pregnancy

Treatment A is probably associated with lower multiple pregnancy rates than Treatment B (RR 0.04, 95% CI 0.01 to 0.15, three RCTs, N = 811,  $I^2 = 23\%$ , moderate quality evidence). This suggests that if the risk of multiple pregnancy following Treatment B is assumed to be 13%, the risk following Treatment A would be between 0% and 2%.

#### Secondary outcomes

##### 1.3 Other adverse events

No studies reported on other adverse events

### 2. Comparison of Treatment B versus Treatment C

#### Primary outcomes

##### 2.1 Live birth

##### 2.2 Multiple pregnancy

#### Secondary outcomes

##### 2.3 Other adverse events

The following wording can be used for interpretation of findings:

Level (quality) of evidence	Important benefit or harm <sup>#</sup> (eg absolute increase or decrease of on average at least 5% in live birth; 1 not in CI)	Less important benefit or harm <sup>#</sup> (eg absolute increase or decrease between 1 and 5% in live birth; 1 not in CI)	No important benefit/harm or null effect
High	improves*	improves slightly	little or no difference in [outcome]
Moderate	probably improves	probably improves slightly	probably little or no difference in [outcome]
Low	may improve	may improve slightly	In case of a wide confidence interval with an absolute difference to the left or right of at least 5% for pregnancy outcomes: <b>We are uncertain of the effect of [intervention]**</b> When the 95% CI of the absolute difference is 5% or less a better statement would

			be: "The analysis ruled out a clinically relevant difference but the quality of the evidence was low or "may have little or no difference" (rare for low quality evidence)
<b>Very low</b>	We are uncertain whether [intervention] improves [outcome]***		
<b>No events or rare events</b>	Use comments in SoF table in a plainer language or summarise the results		
<b>No studies</b>	No studies were found that looked at [outcome]		

\* Substitute the appropriate verb for 'improves' throughout the table, depending on the results: for example, 'increases', 'reduces', 'leads to', 'prevents';

\*\* You can also say "due to wide confidence interval (CI), we are uncertain / it is unclear". Use this wording for moderate quality evidence as well in case of wide CI.

\*\*\* There is a debate about whether results which are rated as 'very low quality' should present numbers or not. Both approaches are currently used.

# What is considered a clinically important benefit or harm? Predefine this in the protocol or update. For instance for live birth we may consider an increase or decrease of at least 5% to be of important benefit or harm

## **PART F - Discussion**

No text should appear directly under this heading

### **Summary of main results**

- o Briefly summarise the main review findings, directly addressing the objectives. Highlight and outstanding uncertainties, balancing important benefits against important harms. Express results in the most consumer-friendly way possible. Refer to quality of evidence (from SoF table)

### **Overall completeness and applicability of evidence**

This section addresses the external validity of the review.

- o Did the included studies answer the review question?
- o Were relevant participants, interventions and outcomes investigated?
- o Do the review findings support current practice?
- o Comment on studies that measured outcomes but had no 'usable' data

### **Quality of the evidence**

This section addresses the internal validity of the review.

- o How robust are the conclusions?
- o Use the GRADE ratings from the Summary of Findings (SoF) table to describe the quality of the evidence for each comparison, and use the footnotes from the SoF table to summarise the limitations of the evidence.
- o Discuss limitations of the review at study and outcome level (e.g. regarding risk of bias), and at review-level (e.g. incomplete identification of studies, reporting bias).

### **Potential biases in the review process**

Comment on the strengths and limitations of the review process

- Were all relevant studies identified?
- Could review authors' methods have introduced bias?

### **Agreements and disagreements with other studies or reviews**

How do the review findings fit into the wider research context?

## ***PART G - Authors' conclusions***

### **Implications for practice**

- We suggest making this identical to the conclusions in the abstract (copy and paste)
- Do not go beyond the evidence reviewed, mention GRADE ratings
- If relevant, summarise the likely benefits and risks/costs of the intervention and for whom it should be considered.

### **Implications for research**

- Which questions have been well answered (no further trials needed)
- Which questions remain unanswered (further trials needed)
- Whether further trials in selected populations are warranted
- Identify any new research areas (dose modification, combined therapies etc).
- If recommending further research, structure the implications for research to address the nature of evidence required, including population, intervention comparison, outcome, and type of study.

### **Differences between protocol and review**

- If planning any departures from Methods specified in protocol, check with editorial base first
- If changes are approved, document and justify the changes in the Differences from Protocol section.

**\*Before checking in your review for editorial approval run a validation report in RevMan.**



## Appendix - Copy-Editing

All Cochrane Reviews (including Protocols and Updates) are copy-edited before publication. Prior to copy-editing, all submissions are checked for readiness for copy-editing. This assessment focuses on areas such as structure and content of key sections, in-text citations, consistency and formatting of outcomes, table formatting, standard of English, and quality of references. Here we provide some tips to help you prepare your review according to the guidelines. To find out more about Cochrane's copy-editing policy and guideline go to [Editorial and Publishing Policy Resource Copy-Editing](#).

### Plain language summary

- Provide explanations in plain English for all medical and scientific terms.

### PRISMA diagram

- Make sure that the numbers of trials included in the diagram add up to the numbers in the text.
- 

### In-Text citations

- Ensure that citations in brackets are located just ahead of punctuation (see [Citing References](#) in the [Cochrane Style Manual](#))

### Characteristics of included studies and Risk of Bias (ROB) Tables

- Don't add full stops at ends of incomplete sentences, e.g. 'Unclear' not 'Unclear.'
- Follow colons with lower case letters (except when followed by a name).
- ROB tables - insert 'Quote' before all quotations. Example: Quote: "Once allocated, the treatment was revealed to both the investigator and the patient."
- Use abbreviations used in text throughout the table.
- Insert a list of abbreviations used in the tables at the end of the tables in the Footnotes section.

### References

- Check the formatting of all references (see [Reference types](#)) including full stops, capitalization in titles, italics, page numbers.
- For references with more than six authors, list the first six authors followed by 'et al'.

### General

- Ensure that all abbreviations are defined in full on first use separately in Abstract, PLS, Main text, and Authors' conclusions.
- 

### Formatting of symbols

- Use 'to' instead of '-' to denote ranges in text (OK to use '-' in tables).
- Use 'mL' and not 'ml' or 'mLs' throughout.
- Use the correct spacing around symbols such as = < > (see [Symbols and special characters](#))
- Use round brackets (find out more about [punctuation](#))